Ophidion CNS Carrier Technology
- Ophidion’s CNS Carrier Technology (or OCCT) is available for partnering.
- We look forward to enabling third parties to enhance the penetration of their pipeline or marketed products (life cycle management) to the brain.
- OCCT can be coupled with small molecules, including peptides, gene silencing therapeutics ( siRNAs and ASOs), and other macromolecules (e.g. antibodies, oligonucleotides, etc.).
Ophidion’s current Partnership
- Ophidion, Inc. and Neuronasal, Inc. Announce Strategic Collaborations to Tackle Parkinson’s Disease, Obesity, and Diabetes via Novel CNS Delivery Platform (Dec. 2025).
Ophidion’s CNS Pipeline
- Ophidion is looking to develop other pipeline products to preclinical proof of concept before out-licensing them to third parties.
- Co-development partners for the Huntington’s (OCCT-HTT siRNA) and cognition (OCCT-lynx1 siRNA) programs in the USA
Partnering Opportunities
Ophidion’s CNS Carrier Technology (OCCT)
-
Available for partnering with third parties’ pipeline or marketed products
Huntington’s Disease
(OCCT-HTT siRNA/HTT ASO)
-
Available for partnering in ex-U.S. regions (Europe, China, and Japan)
-
For the U.S.: looking for co-development partners
Cognition (OCCT-lynx1 siRNA)
-
Available for partnering on a world-wide basis
Other Pipeline Products
-
Parkinson’s Disease
-
Progressive Supranuclear Palsy
-
Alzheimer’s Disease
-
Amyotrophic Lateral Sclerosis (ALS)
-
ALS / Frontotemporal Dementia
-
CNS cancer